Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)

v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Stockholder Deficit TransBiotecInct [Member]
Noncontrolling Interest [Member]
Balance, shares at Jan. 01, 2018 109,409,930 1,388,575
Balance, amount at Jan. 01, 2018 $ (2,964,137) $ 1,096 $ 14 $ 14,785,051 $ (17,703,171) $ (2,917,010) $ (47,127)
Common stock issued to settle accounts payable, shares   91,148          
Common stock issued to settle accounts payable, amount 428 $ 1 427 428
Paid-in capital - fair value of stock warrants granted 10,958 10,958 10,958
Paid-in capital - gain on related party debt conversion 7,776 7,776 7,776
Net Income (Loss) $ (143,870) $ (143,049) $ (143,049) $ (821)
Balance, shares at Mar. 31, 2018 109,501,078 1,388,575
Balance, amount at Mar. 31, 2018 $ (3,088,845) $ 1,097 $ 14 $ 14,804,212 $ (17,846,220) $ (3,040,897) $ (47,948)
Balance, shares at Jan. 01, 2019 116,751,078 1,388,575
Balance, amount at Jan. 01, 2019 $ (3,423,431) $ 1,172 $ 14 $ 14,887,804 $ (18,262,136) $ (3,373,146) $ (50,285)
Paid-in capital - fair value of stock warrants granted 22,665 22,665 22,665  
Paid-in capital - gain on related party debt conversion 8,113 8,113   8,113  
Net Income (Loss) (139,056) (138,289) (138,289) (767)
Common stock issued for cash, amount $ 39,000 $ 350 $ 38,650 $ 39,000
Common stock issued for cash, shares   35,454,547          
Balance, shares at Mar. 31, 2019 152,205,625 1,388,575
Balance, amount at Mar. 31, 2019 $ (3,492,709) $ 1,522 $ 14 $ 14,957,232 $ (18,400,425) $ (3,441,657) $ (51,052)